Novel Neuroprotective/Anti-inflammatory Therapy for Ischemic Stroke

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$2,176,571.00
Award Year:
2009
Program:
SBIR
Phase:
Phase II
Contract:
2R44NS062625-02
Award Id:
89423
Agency Tracking Number:
NS062625
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
ANGION BIOMEDICA CORP, 1050 Stewart Ave., GARDEN CITY, NY, 11530
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
053129065
Principal Investigator:
DAVID SMITH
(516) 326-1200
DSMITH@ANGION.COM
Business Contact:
EDWARD SMITH
() -
igoldberg@angion.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Stroke is leading cause of morbidity and mortality in the US. Research on the pathophysiological basis of stroke has produced new paradigms for prevention and treatment, but translation of these approaches into improved clinical outcomes has proved to be painfully slow. Preventive strategies focus primarily on reducing or controlling risk factors such as diabetes, hypertension, cardiovascular disease, and lifestyle; in patients with severe stenosis, carotid endarterectom y may be indicated. Cerebral angioplasty is used investigationally, but the high restenosis rates observed following coronary angioplasty suggest this approach may pose unacceptable risk for many patients. Therapeutic strategies focus primarily on acute tr eatment to reduce injury in the ischemic penumbra, the region of reversibly damaged tissue surrounding an infarct. Thrombolytic therapy has been shown to improve perfusion to the ischemic penumbra, but it must be administered within three hours of the onse t of infarction. However, new clinically useful agents must be efficacious when given at considerably longer intervals after the onset of ischemia as most stroke patients do not arrive for medical treatment but for several hours, much later than the short, efficacious window of other agents such as the thrombolytics. Targeting Poly (ADP-ribose) polymerase (PARP-1) in the setting of ischemic stroke may provide therapeutic benefit over a long time window, as research studies have demonstrated that PARP-1 inhi bition will protect the neurovasculature from the primary ischemic insult and also later when additional cells die as the result of the induced inflammatory response. In this proposed study we will investigate the acute and long-term effects of our lead co mpound, ANG-2864 in rat models of temporary and permanent ischemic stroke. PUBLIC HEALTH RELEVANCE: Stroke is leading cause of morbidity and mortality in the US. Research on the pathophysiological basis of stroke has produced new paradigms for prev ention and treatment. Drugs that inhibit the enzyme, Poly (ADP- ribose) polymerase (PARP-1) in the setting of ischemic stroke may provide therapeutic benefit over a longer time window, as studies have demonstrated that PARP-1 inhibition will protect neuron al cells from the primary ischemic insult and also later when additional cells die as the result of the induced inflammatory response

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government